PHILADELPHIA — (Jan. 24, 2019) — Wistar scientists and collaborators demonstrated the utility of an optimized synthetic DNA vaccine platform for rapidly inducing immunity against unique combination…
PHILADELPHIA — (January 8, 2019) — The Wistar Institute, along with partners Penn Medicine and Inovio Pharmaceuticals, Inc. (NASDAQ:INO), announce that the FDA has approved the initiation of a firs…
PHILADELPHIA — (Dec. 13, 2018) — Are we looking at the masked exoskeleton of cinema’s latest superhero, a firework and an amoeba? No, these images are the eye of a beetle, the central region of the…
PHILADELPHIA — (Nov. 15, 2018) — Researchers at The Wistar Institute have developed novel synthetic DNA-encoded monoclonal antibodies (DMAbs) directed against PCSK9, a protein key to regulating cho…
PHILADELPHIA — (Nov. 13, 2018) — Scientists at The Wistar Institute and collaborators have successfully engineered novel DNA-encoded monoclonal antibodies (DMAbs) targeting Zaire Ebolavirus that we…
PHILADELPHIA — (Nov. 13, 2018) — According to new research from The Wistar Institute, the S100A14 protein is expressed at higher levels in people who inject drugs and remain uninfected despite many…
PHILADELPHIA — (Oct. 15, 2018) — Researchers at The Wistar Institute have characterized the function of neutrophils, a type of white blood cells, during early stages of tumor progression, showing t…
PHILADELPHIA — (October 10, 2018) — A novel synthetic DNA vaccine developed based on technology pioneered by scientists at The Wistar Institute Vaccine & Immunotherapy Center offers complete pr…
PHILADELPHIA — (Oct. 8, 2018) — Scientists at The Wistar Institute have unraveled a mechanism of resistance to EZH2 inhibitors in ovarian cancers with mutations in the ARID1A gene. The study, publi…
PHILADELPHIA — (Oct. 4, 2018) — Wistar scientists and collaborators demonstrate for the first time that through engineering constructs, they can express DNA-encoded monoclonal antibodies (DMAbs) ta…
